Under construction – not a live service
Sign in
Taking people in TaiwanPhase 2

Tests surovatamig in adults with returned B-cell non-Hodgkin lymphoma

Tests surovatamig alone in adults whose B-cell lymphoma has returned or not responded.

Key facts

Who runs it
AstraZeneca
Where
Kaohsiung City, Taichung, Tainan, and Taipei, TaiwanSee the 4 sitesAlso in 15 other countries, 78 sites
Registry title
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Status
Recruiting
Phase
Phase 2
People taking part
270 people, planned
Started
27 Nov 2024
Expected to end
21 Oct 2032
Type of study
Interventional, 2 groups
Treatments tested
  • Surovatamig
Record updated
14 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose follicular lymphoma or large B-cell lymphoma came back or did not respond after at least 2 earlier treatments. All get surovatamig (AZD0486).

Age
18 years and older
Sex
Men and women can join
Disease stage
Follicular lymphoma (Module 1) or large B-cell lymphoma (Module 2) that came back or did not respond after at least 2 prior lines of therapy. Disease must show on a scan (FDG-avid) with at least one measurable lesion.
Earlier treatment
At least 2 prior lines of therapy. Cannot join: T-cell engager within 8 weeks, autologous stem cell transplant within 12 weeks, CAR T-cell therapy within 6 months, or allogeneic stem cell transplant within 24 weeks before the first dose.
Biomarker or test result
CD-19 present in the lymphoma cells, confirmed locally after progression from the last CD 19 directed therapy.

Main reasons for not taking part

  • Chronic lymphocytic leukemia (CLL), Burkitt lymphoma or Richter's transformation
  • Active lymphoma in the brain or spinal fluid (CNS), or leukemic form of the lymphoma
  • Serious brain or nerve condition, such as epilepsy, stroke, dementia or Parkinson's disease
  • Need for long-term immune-suppressing treatment
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 2 criteriaShow less

Other criteria

  • Key Inclusion Criteria:; Aged 18 years old and above; Histologically confirmed relapsed refractory FL (Module 1) and LBCL (Module 2) after at least 2 prior lines of therapy; ECOG performance status 0 to 2; Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy; FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as > 1.5 cm in its longest dimension), or extranodal lesion (defined as > 1.0 cm in its longest dimension); Adequate hematological function: ANC ≥ 1000/mm3, platelets; 75,000/mm3, hemoglobin ≥ 9 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening; Adequate liver function: total bilirubin <1.5x ULN, AST/ALT ≤ 3xULN or < 5 × ULN in the presence of lymphoma involvement of the liver; Adequate renal function: creatinine clearance (CrCl) of ≥ 45 mL/min; Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) ≥ 45% by echocardiogram or MUGA; The above is a summary, other inclusion criteria details may apply
  • Key Exclusion Criteria:; Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation; Active CNS involvement by B-NHL; Leukemic presentation of B-NHL; History of a clinically relevant CNS medical condition or pathology that required treatment in the preceding year, is currently symptomatic, or that the treating investigator considers to have the potential to interfere with the evaluation of safety, such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, neurodegenerative disorder including Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis or other severe mental illness; Prior therapy with T-cell engager (TCE) within 8 weeks, autologous Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, CAR T- cell therapy within 6 months, or prior allogeneic HSCT within 24 weeks of first dose of surovatamig; Requires chronic immunosuppressive therapy; Unresolved non hematological AEs ≥ Grade 2 from prior therapies; history of ≥ Grade 3 CRS or neurotoxicity from prior CAR-T or TCE therapy; History of major cardiac abnormalities; If female, participant must not be pregnant or breastfeeding; The above is a summary, other exclusion criteria details may apply

Where in Taiwan

Also in 15 other countries, 78 sites

  • Kaohsiung CityHospital not named in the registryNo longer taking part
  • TaichungHospital not named in the registryTaking people
  • TainanHospital not named in the registryTaking people
  • TaipeiHospital not named in the registryTaking people

About the trial

What the trial wants to find out

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.

The 2 groups in the trial

  • Module 1: Surovatamig Monotherapy in Participants with Relapsed or Refractory Follicular LymphomaTreatment being tested

    In Module 1, the efficacy and safety of surovatamig at the RP2D will be evaluated in R/R FL. Surovatamig will be administered as intravenous infusion.

    Treatment: Surovatamig

  • Module 2: Surovatamig Monotherapy in Participants with Relapsed or Refractory LBCLTreatment being tested

    In Module 2, the efficacy and safety of surovatamig at the RP2D will be evaluated in R/R LBCL. Surovatamig will be administered as intravenous infusion.

    Treatment: Surovatamig

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)
Plain-language title
Tests surovatamig in adults with returned B-cell non-Hodgkin lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 10 November 2026.
Record updated
14 October 2026